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Abstract 
 
Background: Inflammation both accelerates atherosclerosis and contributes to the activation 
and rupture of the atherosclerotic plaque. Several markers of inflammation, such as C-reactive 
protein (CRP), have shown prognostic merit in patients with acute coronary syndromes 
(ACS).  
Aims: To investigate the association between circulating levels of some markers with relation 
to inflammation – osteoprotegerin (OPG), Chemokine (C-X-C motif) ligand 16 (CXCL16) 
and chromogranin A (CgA) – and prognosis in a population of patients with ACS. 
Material and methods: Patients aged 18-79 years who were admitted to the coronary care 
unit at a university hospital with an ACS had blood drawn within 24 hours and after 3 
months; OPG, CXCL16 and CgA concentrations were determined by an enzyme 
immunoassay using commercially available antibodies. Echocardiography with determination 
of the left ventricular ejection fraction (LVEF) was performed within 5 days of admission.  
Mortality data were obtained from the Swedish National Population Registry and morbidity 
data from the Swedish Hospital Discharge Registry. The length of follow-up was a median of 
81-92 months. 
Results: Higher OPG levels were associated with an increased likelihood of ST-elevation 
myocardial infarction (MI), markers of myocardial damage and indices of cardiac dysfunction 
such as LVEF and B-type natriuretic peptide (BNP). The patients with the higher levels were 
also more likely to have a history of heart failure (HF) and to be hypotensive on arrival. The 
circulating OPG levels were predictive of long-term mortality and the incidence of 
rehospitalization due to HF, a relationship that remained significant after adjustment for 
clinical risk factors and, in a subgroup where such data were available, after further 
adjustment for LVEF, CRP, BNP and troponin. The C-statistics of the prognostic information 
offered by OPG were significantly better than CRP and troponin and similar to BNP and 
LVEF. For CXCL16, as for OPG, higher levels were associated with higher age and ST-
elevation MI. CXCL16 predicted long-term mortality, future hospitalizations for HF and new 
MI, also after adjustment for clinical risk factors. After further adjustments for LVEF, CRP, 
proBNP and troponin, only the combination of OPG and CXCL16 serum levels predicted 
cardiovascular (CV) and all-cause mortality, as well as HF rehospitalizations. This was true 
for both the long term and short term, even after adjustment for the Global Registry of Acute 
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Coronary Events (GRACE) score. Serum levels of OPG and CXCL16 at day 1 and 3 months 
after ACS were similarly associated with outcome. 
CgA was also an independent predictor of mortality and HF after adjustments for 
conventional risk factors, including troponin, and was still significantly associated with 
mortality after further adjustment for LVEF and proBNP.  
 
Conclusions: Even after adjustment for conventional risk markers, serum levels of OPG, 
CXCL16 and CgA were predictive of long-term mortality and rehospitalizations due to HF in 
patients with ACS. !"#$%&'# (')*+# ,-$,#$#.'/01*$,1'*#'(#234#$*+#565789#&":)/# %";"%&#<$&#=:"+1.,1;"#'(#/':,$%1,>#$*+#?@#-'&=1,$%1A$,1'*&# B# $*+#C$;"#/':"# 1*(':/$,1'*# ,-$*#"1,-":#/$:D":#$%'*"#B#1*#0',-#,-"#%'*C#,":/#$*+#,-"#&-':,#,":/E#";"*#$(,":#$+F)&,/"*,#(':#,-"#4GH5I#&.':"J#Inflammatory markers appear to add prognostic value above and beyond 
clinical information.#
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Svensk sammanfattning 
 
Ett akut koronart syndrom är ett samlingsnamn för hjärtinfarkt och instabil kärlkramp. Den 
underliggande processen är ateroskleros (åderförkalkning/ åderförfettning). Ateroskleros är en 
process som börjar redan i tidig barndom men vanligen först i övre medelåldern börjar ge sig 
till känna i form av kärlkramp, hjärtinfarkt, stroke eller perifer artärsjukdom. Ateroskleros 
anses numera vara en inflammatorisk sjukdom som sätts igång av ansamling av blodfett, det 
sk onda kolesterolet, i kärlväggen. Fetter ansamlas i väggen på artärer (=pulsådror) och vissa 
av immunförsvarets celler medverkar och bidrar till utvecklingen av “plack” som är 
lokaliserade aterosklerosförändringar som buktar in i kärlet. Om ett plack spricker så att 
innehållet kommer i kontakt med blodet aktiveras trombocyter (=blodplättar), som klumpar 
ihop sig och byggs på med andra blodlevringsämnen så att en tromb (=propp) bildas. Den kan 
växa sig stor nog att täppa till kärlet på plats eller embolisera (=lossna och fastna längre ut i 
kärlet där det är smalare). Det blir då syrebrist i den vävnad som försörjts via kärlet och om 
syrebristen får fortgå kommer vävnaden att dö – den har drabbats av en infarkt. Om placket är 
beläget i något av hjärtats blodkärl uppkommer en hjärtinfarkt. Kärlkramp (“angina pectoris”) 
beror oftare på att kärlet har blivit så försnävat av aterosklerosförändringarna att tillräckligt 
mycket blod (och därmed också syre) inte kan transporteras till hjärtmuskeln i vissa 
situationer – ofta kroppslig ansträngning.  
I Sverige är hjärt-kärlsjukdom den bakomliggande dödsorsaken hos 42 % av kvinnorna och 
41 % av männen som dör. 2007 inträffade 665 fall av akut hjärtinfarkt per 100 000 män och 
467 fall per 100 000 kvinnor !20 år. Dödligheten minskar – bland annat pga att kriterierna 
vidgats och mindre hjärtskador än tidigare ger diagnosen hjärtinfarkt, men också för att flera 
behandlingar tillkommit som förlänger livet hos personer med hjärt-kärlsjukdom och för att 
förebyggande åtgärder börjat få effekt- men fortfarande dör drygt 15 % av dem som vårdas på 
sjukhus för en hjärtinfarkt inom 28 dagar enligt Socialstyrelsens siffror. 
 
Målsättningen med avhandlingen var att undersöka om några ämnen som stiger vid 
inflammation och därför kan ses som markörer för farlig ateroskleros skulle kunna användas 
för att bättre gruppera patienter med ett akut koronarsyndrom utifrån deras risk att dö eller få 
en ny hjärtinfarkt alternativt utveckla hjärtsvikt.  
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Cytokiner är små proteiner som används för signalering mellan celler. Ofta utsöndras de från 
immunförsvarets celler men de kan också komma från andra celltyper och de kan vara 
membranbundna, dvs sitta i cellens yttre hölje. Osteoprotegerin (OPG) är en cytokin som är 
inblandad i den ständiga förnyelsen av vår benstomme men som också stiger i blodet vid ett 
akut koronart syndrom och vid hjärtsvikt. CXCL16 är en cytokin som finns i fler former. En 
form är bunden till cellers ytterhölje och fungerar som mottagare och ingång i vissa celler för 
“härsket kolesterol”. Kolesterolfyllda “skumceller” är viktiga byggstenar i det aterosklerotiska 
placket. I sin lösliga form är CXCL16 en signal till celler från immunförsvaret och glatta 
muskelceller om att komma närmare den cell som släpper ut CXCL16. Både OPG och 
CXCL16 finns i aterosklerotiska plack och i sviktande hjärtmuskel och verkar där bidra till 
nedbrytning av mikroskopisk stödjevävnad kallad matrix. Detta kan vara en mekanism som 
ökar risken för plackruptur och som driver på hjärtsviktsutveckling. Chromogranin A (CgA) 
som är en granin, inte en cytokin, ligger lagrat tillsammans med stresshormoner i bl a 
hormonbildande vävnad. De släpps ut tillsammans som svar på olika typer av “stress” men 
CgA ligger kvar längre i blodet. CgA finns i förhöjda nivåer i blodet hos personer med 
hjärtsvikt och återfinns också i sviktande hjärtmuskel.  
I arbetena som ingår i denna avhandling undersökte vi relationen mellan koncentrationen av 
de här inflammationsmarkörerna i blodprover tagna det första vårddygnet hos patienter med 
akuta koronara syndrom och dödlighet samt hjärtrelaterad sjuklighet under en uppföljningstid 
av c:a 7 år.  
Bland de patienter vi undersökte var högre nivåer av OPG, CXCL16, en kombination av 
dessa två eller CgA förenat med en ökad dödlighet, även efter att vi korrigerat för kliniska 
riskfaktorer. Likaledes var höga värden av OPG, CgA och CXCL16 eller OPG/CXCL16-
kombinationen förknippade med en ökad risk för att behöva sjukhusvårdas pga hjärtsvikt, 
även efter korrigering för kliniska riskfaktorer. CXCL16 var också förknippat med en ökad 
risk för att komma att sjukhusvårdas för hjärtinfarkt. Resultaten var oberoende av vilken 
diagnos patienten fick vid det första vårdtillfället, och de kan bidra till utformningen av en 
optimerad riskstratifiering och förebyggande behandling. 
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Abbreviations 
 
ACE-I Angiotensin-converting enzyme inhibitor 
ACS Acute coronary syndrome 
ADAM A disintegrin and metalloproteinase domain 
ARB  Angiotensin receptor blocker 
BMI Body mass index 
BNP B-type natriuretic peptide 
BP Blood pressure 
CABG Coronary artery bypass grafting 
CAD Coronary artery disease 
CCU Coronary care unit 
CgA Chromogranin A 
CI Confidence interval 
CK-MB Creatinine kinase MB fraction 
CRP C-reactive protein 
CV Cardiovascular 
CXCL16 Chemokine (C-X-C motif) ligand 16 
DC Dendritic cell 
EC Endothelial cell 
EDTA Ethylenediaminetetraacetic acid 
ESC European Society of Cardiology 
GFR Glomerular filtration rate 
HF Heart failure 
HR Hazard ratio 
IFN Interferon 
IL Interleukin 
LAD Left anterior descending coronary artery 
LDL Low density lipoprotein 
LVEF Left ventricular ejection fraction 
M-CSF Macrophage-colony stimulating factor 
MI Myocardial infarction 
NSTEMI Non-ST-elevation myocardial infarction 
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NF-κB Nuclear factor-kappa-B 
OPG Osteoprotegerin 
PCI Percutaneous coronary intervention 
PRACSIS Prognosis and risk in acute coronary syndrome in Sweden 
RANK Receptor activator of nuclear factor-kappa-B 
RANKL  Receptor activator of nuclear factor-kappa-B 
SD Standard deviation 
SMC Smooth muscle cell 
SR Scavenger receptor 
SR-PSOX Scavenger receptor for phosphatidylserine and oxidized LDL 
STEMI ST-elevation myocardial infarction 
TGF Transforming growth factor 
TNF Tumor necrosis factor 
TnI Troponin I 
TnT Troponin T 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
UAP Unstable angina pectoris 
VCAM-1 Vascular cell adhesion molecule 1 
 
 
 
 

   
 
Introduction 
In this thesis, the usefulness of a few markers of inflammation is examined with regard to 
their ability to predict morbidity and mortality in a population of patients experiencing an 
ACS.  
As the majority of research articles on the subject tend to begin, cardiovascular (CV) disease 
is the leading cause of death in the western world.1 In fact, searching for the phrase “CV 
disease is the leading cause of death in the western world” on the search engine Google.com 
gives about 55.600 replies. In 2001, ischemic heart disease was the leading cause of death not 
only in high-income countries but also in low- and-middle-income nations.1  
 
Acute coronary syndromes 
ACS is a term used for MI with and without ST elevation (STEMI and NSTEMI respectively) 
and unstable angina pectoris (UAP). It is most commonly caused by the rupture of an 
atherosclerotic plaque with subsequent thrombus formation, followed by ischemia and often 
the necrosis of dependent heart muscle.  
MI is the most common cause of death in middle-aged men and women in Sweden.2 In 2007, 
there were 665 acute MIs per 100,000 men and 462 per 100,000 women aged ≥ 20 years. In 
1995, 41% of men who had heart attacks died within 28 days, as did 45% of women.3 In 
2001, the diagnostic criteria for acute MI were changed, resulting in more patients, with less 
serious disease, being diagnosed with MI. Because of this, the mortality from MI in Sweden 
appeared to decrease even more rapidly than was actually the case. In 2007, the lethality 
within 28 days of MI was down to 28% for men, and 32% for women.3 The main reason for 
the decrease in mortality, however, is the reduction of risk factors in the Swedish population, 
and the second reason is improved treatment.4  
In Sweden in 2008, CV disease was the underlying cause of death in 42% of women and 41% 
of men.3 Both the incidence and mortality of MI are strongly related to both age and gender; 
after adjustment for age, men are almost twice as likely to die from MI as women.3  
Myocardial infarction 
An acute MI is defined as myocardial cell death due to prolonged myocardial ischemia.  
It is the necrosis of cardiac myocytes in response to ischemia due to insufficient blood supply, 
usually secondary to arterial occlusion, commonly manifested as retrosternal chest 
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pain/pressure, frequently accompanied by ECG changes. The present definition of MI was 
introduced in 2007 by representatives of the American College of Cardiology, the American 
Heart Association, the European Society of Cardiology (ESC) and the World Heart 
Foundation, making troponins the preferred biomarkers. An increase in the cardiac troponin 
concentration (I or T) greater than the 99th percentile of a reference population together with 
evidence of ischemia with at least one of the following:  
• Symptoms of ischemia 
• ECG changes of new ischemia (new ST-T changes or new left bundle branch block)  
• Development of pathological Q waves on the ECG 
• Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality 
are considered to be diagnostic of MI.5  
Unstable angina pectoris 
UAP can be new-onset angina or a sudden change in the pattern of previously stable angina, 
including pain during rest and accelerating angina, which may signal an impending heart 
attack. The line between what is UAP and what is MI has been moved with the new definition 
of MI, resulting in more patients who would previously have been given the diagnosis of 
UAP now receiving a diagnosis of NSTEMI.  
 
Endpoints 
Mortality 
CV mortality dominates in patients who have had an ACS and is caused either by a new 
MI/related sudden death or by HF/lethal arrhythmia. In a previous study on the PRACSIS 
cohort, 5-year mortality was higher in NSTEMI patients before, but not after adjustment for 
risk markers.6 In a recent study on the UK and Belgian part of the GRACE, 5-year morbidity 
and mortality were as high in NSTEMI and UA patients as in those with STEMI.7  
 
Ischemic heart failure 
HF is a common disease. In Sweden, an estimated 200,000 have HF that gives symptoms and 
at least as many have latent HF. The prevalence increases with age; about 1% of 50-year-olds 
have HF, as compared to 10% of those aged 70 and over. In 2007 in Sweden, 22,000 patients 
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were hospitalized for HF and 3,800 died.8 Mortality is high in subjects with HF; in a recent 
article, HF was associated with an unadjusted case-fatality rate of 59% within 5 years in 
Sweden.9 Early diagnosis and treatment improve both the prognosis and quality of life.10-13 
HF results from a variety of underlying conditions, such as ischemic heart disease, 
hypertension, valvular disease, cardiomyopathies, myocarditis and diabetes. Several 
definitions of HF have been suggested over the years. The ESC states that HF is a syndrome 
with the following traits:14 
• HF symptoms; typically shortness of breath and/or fatigue 
• Signs of fluid retention such as pulmonary congestion or ankle swelling 
• Objective evidence of an abnormality of the structure or function of the heart at rest 
 
HF is a progressive disorder characterized by the dysregulation of several physiological 
systems. The first step is usually damage to the myocardium with ensuing remodeling, pump 
dysfunction, neurohormonal activation and salt-water retention. Both neurohormonal 
activation and hydrosaline retention are compensatory mechanisms that initially increase 
stroke volume and peripheral resistance, i.e. have inotropic effects to help maintain the mean 
arterial perfusion pressure. Later in the process, however, these mechanisms prove 
deleterious. The heart is subjected to structural changes: the loss of microfilaments, apoptosis 
and the disorganization of the cytoskeleton, disturbances in calcium hemostasis, alterations in 
receptor density, signal transduction and collagen synthesis and the degradation of the matrix 
by matrix metalloproteinases (MMPs). 
Recurrent MI 
In the UK-Belgian cohort of the GRACE, about 18.2% of the patients with an index diagnosis 
of ACS experienced one or more MIs during 5 years of follow-up.7 On average, each patient 
was rehospitalized 1.6 times for suspected ACS, less than 10% of those hospitalizations, 
however, resulted in a new diagnosis of MI.  
Stroke 
According to the definition used by the World Health Organisation (WHO), a stroke is “a 
neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted by 
death within 24 hours”. There are two main categories of stroke: ischemic and hemorrhagic, 
with ischemic being the most common. Ischemic strokes result from the interruption of blood 
supply by a clot, either formed in the arteries; locally (thrombotic) or elsewhere in the body 
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(embolic); or in the veins. Hemorrhagic stroke is caused by the rupture of a blood vessel. 
Stroke is, after ischemic heart disease ander cancer, the third leading cause of death in 
Sweden. In the GRACE publication mentioned above, about 12.9% of ACS patients sustained 
one or more strokes during 5-year follow-up.7  
 
Clinical risk stratification 
A large number of models for risk stratification in patients with an ACS have been proposed; 
they are composed of clinical variables, laboratory markers or both. Many of the risk scores 
have been derived from large clinical trials, such as Thrombolysis In Myocardial Infarction 
(TIMI), perhaps the one most widely used, even though the GRACE score has been shown to 
be superior at least in NSTEMI and UAP.15, 16 Moreover, clinical trials tend to have strict 
criteria for inclusion and exclusion, making the results less generalizable than those from a 
registry such as GRACE (for further information see below). 
Clinical risk factors 
The Framingham heart study17 first introduced the term “risk factor” in modern medical 
literature. The CV risk increases with age, a family history of CV disease and male gender, ie 
factors that are not possible to modify. There are, however, risk factors that can also be 
controlled and risk factors we still have some hope of being able to treat.  
 
Smoking is known not only to accelerate atherosclerosis but also to increase the risk of an 
acute event and smokers are more likely to present with STEMI than non-smokers.18 In areas 
where bans on smoking have been evaluated, rates of MI have decreased,19-21 even in areas 
were MI rates were increasing at the time.22 Smokers actually have a better prognosis when 
having an MI, but this is explained by the fact that they are more likely to have an MI at a 
younger age.23, 24 In several large, observational studies, smoking cessation in patients with 
known coronary artery disease (CAD) is associated with a substantial reduction in mortality 
compared with those that continue to smoke. In one study, a 36% reduction in the crude 
relative risk (RR) of mortality for patients with CHD who quit compared with those who 
continued smoking (RR, 0.64; 95% CI, 0.58-0.71) was observed.25 Diabetes and its precursor, 
reduced glucose tolerance, are strong risk factors, but they are possible to affect or even 
prevent by regular exercise and maintaining a normal weight. Mortality is high in diabetics 
after a first MI,26 and women younger than 65 years with diabetes have a poorer outcome than 
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men after MI.27 Obesity in itself, particularly abdominal obesity, increases the risk of CAD. 
Hypertension, especially high systolic pressure, is a risk factor for CV events and 
antihypertensive drug treatment reduces the risk. 28 Dyslipidemia, one of the dominant risk 
factors for atherothrombosis, can be a result of both hereditary factors and lifestyle. 
Dyslipidemia, although often referred to as “hypercholesterolemia”, refers not only to high 
circulating levels of LDL, the “bad cholesterol” and lipoprotein a, but also to decreased levels 
of HDL and to increased levels of triglycerides. The lowering of cholesterol with statins 
improves survival and reduces CV events in patients with CAD.29 Statin treatment also 
reduces mortality after MI.30 Even mildly impaired renal function is associated with an 
increased risk of MI and mortality in the general population.31 The Cockcroft-Gault method 
for estimating creatinine clearance is better than the Modification of Diet in Renal Disease 
(MDRD) method at predicting outcome after MI,32 but cystatin C could be a better measure 
than creatinine.33-35 Obesity as measured by waist-to-hip ratio is also a major risk factor.36 
 
Dietary factors play a role; the dietary approaches to stop hypertension (DASH) diet reduces 
CV risk compared to both a diet rich in fruit and vegetables and a control diet while a diet rich 
in fruits and vegetables reduces CV risk compared to controls.37 What food is rinsed down 
with matters, too; drinking too little is related to increased coronary risk, while high alcohol 
consumption (> 14 drinks a week if you are a man and > 9 drinks if you are a woman) is 
associated with increased mortality and a risk of alcohol-related health problems.38, 39 
Hyperhomocysteinemia, which may be caused by hereditary factors, renal impairment and 
lack of vitamins B12, B6 and folic acid, is associated with an increased risk of CAD. 40 Since 
there is a mechanistic explanation in that homocysteine appears both to damage the 
endothelium, thereby facilitating plaque formation, and to be pro-thrombotic, it was believed 
that homocysteine might be a treatable risk factor, by supplementing the above-mentioned 
vitamins. According to three recently published randomized trials, however, folate and B12 
supplementation are probably neither friend nor foe.41-43 Lack of physical activity is a major 
risk factor and aerobic training like walking seems to be protective.44, 45 Depression is 
associated with a poorer prognosis in ACS.46, 47 Personality is also of importance. Those 
people who have a propensity towards psychological stress9 run a higher risk, and so do those 
displaying cynical hostility.48 The effects seen in the hostile, however, appear to be mediated 
by behavioral risk factors: they are not nice to themselves either. 
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Scoring systems  
A number of scoring systems have been developed for risk stratification in the general 
population (Framingham) and in coronary disease patients (TIMI, GRACE). For ACS 
patients, GRACE is perhaps the most frequently applied scoring system and it appears to have 
some advantages.15, 16 The Global Registry of Acute Coronary Events (GRACE) is a large 
multinational registry of ACS patients49 from which a risk prediction model has been 
developed and further elaborated on. The original GRACE score was created as a prediction 
tool for in-hospital mortality in ACS50 and it is sometimes referred to as the Granger score. 
The model consists of 8 parameters: age, Killip class, systolic blood pressure, ST-segment 
deviation, cardiac arrest during presentation, serum creatinine level, positive initial cardiac 
enzyme findings and heart rate and it has a very good discriminatory ability. The C-statistics 
were 0.83 and 0.84 in the derived and confirmation GRACE data set respectively and 0.79 in 
the GUSTO-IIb database that was used for external validation. Another version of the model, 
tailored to predict 6-month mortality across the spectrum of ACS, used 9 variables: age, 
history of MI, history of HF, increased pulse rate at presentation, lower systolic blood 
pressure at presentation, elevated initial serum creatinine level, elevated initial serum cardiac 
biomarker levels, ST-segment depression on the presenting electrocardiogram and not having 
a percutaneous coronary intervention performed in hospital. The C-statistics were 0.81 for the 
development cohort and 0.75 for the validation cohort.51 Another version of the score uses 9 
parameters to predict death and the composite variable of death and MI over the 6 months 
after presentation with an ACS:52 age, development or history of HF, peripheral vascular 
disease, systolic blood pressure, Killip class, initial serum creatinine concentration, elevated 
initial cardiac markers, cardiac arrest on admission and ST segment deviation. The discharge 
version of the score has been shown to predict mortality over up to four years of follow-up53 
and, in a recently published article, up to six years.54 The Granger score predicted HF as well 
as mortality in a recent publication.55 The C-statistic was GRACE 0.663 (95% CI 0.554-
0.773), p=0.010, as compared to that of BNP: 0.689 (95% CI 0.565-0.812), p=0.003. 
However, in that respect, the thrombolysis in MI risk index (TRI) did even better: TRI 0.714 
(95% CI 0.609-0.819), p= 0.001. 
Risk markers 
Risk determinants are risk factors (the players) and markers (the innocent bystanders). 
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Since the number of research articles on new CV markers is growing rapidly, Morrow and de 
Lemos postulated three criteria in Circulation in 200756 for the appraisal of their clinical 
value:  
(1) Can the clinician measure the biomarker?  
(2) Does the biomarker add new information? 
(3) Will the biomarker help the clinician to manage patients? 
 
With the publication of INTERHEART, a large case-control study that concluded that more 
than 90% of CV disease can be attributed to 9 conventional risk factors,57 those opposed to 
further research on risk determinants appeared to be right – could laboratory markers really 
add anything of real value to that? It appears, however, that they actually can. C-statistics 
nearing 1 are not the only measures of a good risk marker in CVD/CHD.58 Also, 
INTERHEART did not specifically study ACS patients. Khan et al. actually showed that NT-
proBNP is better than the TIMI risk score at predicting death after MI.59 
 
i. Markers of myocyte necrosis 
In 1954, aspartate aminotransferase (AST), a non-specific marker of cytoplasmatic 
constituents, was introduced as the first biomarker of myocardial injury. Then came 
measurements of enzyme activity, followed by markers more specific to the heart, such as 
CK-MB measured by immunoassay. Only 20 years ago, these markers of myocyte necrosis 
were the only risk markers known and used in ACS patients. Now, the most commonly used 
markers are the troponins – in the heart, three types exist: TnT, TnI and TnC, but only I and T 
are heart specific and commercially available as markers. With troponins, the opportunity not 
only to diagnose myocardial injury but also to identify patients running a high risk of 
myocardial injury made its appearance. Since several clinical conditions apart from MI cause 
an increase in circulating troponin levels, the diagnosis of MI now requires troponin elevation 
within an adequate clinical context. Both TnT60-62 and TnI63, 64 have been shown to predict 
mortality in ACS.  
 
ii. Markers of cardiac function  
B-type natriuretic peptide (BNP) is commonly used as a blood test for cardiac function and 
neurohormonal activation. It is a natriuretic hormone that is produced by myocytes in the 
ventricle wall of the heart in response to LV stress. ProBNP, consisting of 108 amino acids, is 
its precursor. It is cleaved into BNP, a 32 amino acid polypeptide, 3.5 kDa in size, and NT-
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proBNP, which is 76 amino acids long and 8.5 kDa in size, biologically inactive and has a 
longer half-life than BNP, approximately 120 minutes and approximately 20 minutes 
respectively. Since BNP levels are significantly higher in patients with HF than in healthy 
subjects, or subjects with a cause for dyspnea other than HF, it is frequently used as a 
diagnostic test for ruling HF in or out. BNP is an indicator of LV ejection fraction (EF) and 
predicts mortality after MI.65 It is also predictive of mortality in other ACS patients.66 Serum 
levels of BNP and proBNP are lower in obese subjects with HF.67 Reduced levels are seen in 
treatment with angiotensin converting enzyme inhibitors (ACE-I), 68 angiotensin receptor 
blockers (ARB), aldosterone antagonists, 69 and diurectics may reduce BNP beyond 
hemodynamic effects. 70 Levels may be elevated in conditions other than HF, such as LV 
hypertrophy, myocardial ischemia, tachycardia, right ventricular overload, cirrhosis, low 
glomerular filtration rate (GFR), diabetes and severe infection, and the levels are generally 
higher in women than in men and also increase with age. BNP is eliminated from plasma by 
natriuretic peptide receptors and degraded by neutral endopeptidases, but also through 
glomerular filtration, the only route of elimination of importance for NT-proBNP. 71, 72 It 
appears that BNP has greater variability, both within hour and within week, than NT-proBNP, 
at least in stable HF patients.73 So which marker should be used? So far, no difference of any 
real importance relating to prognosis potential has been demonstrated. 74, 75 
 
Echocardiographic measurement of LVEF is not only a diagnostic tool in HF, it is also a 
prognostic marker in ACS patients76 and provides additional prognostic information to the 
TIMI risk score.77 In PRACSIS, we have demonstrated an association between LVEF and 
mortality (dichotomized, LVEF <40% and ≥40%) that was significant after adjustment for 
clinical information.78 
Pathophysiology and search for new risk markers 
Atherosclerosis is the underlying process in MI, angina, stroke and ischemic heart HF. The 
pathophysiology of atherosclerosis has attracted enormous interest over time and it has 
become evident that inflammation is a key factor.79-81 Lately, therefore, efforts to detect not 
only vulnerable plaque but also the vulnerable patient have increasingly involved 
inflammatory and other biomarkers. 
The word atherosclerosis is Greek and consists of the word athere which actually means 
“porridge” but is used to describe the focal accumulation of lipids, and sclerosis, meaning 
“hardening” that refers to the thickening of the arterial intima.  
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Rudolf Virchow was perhaps the first to consider inflammatory changes in the artery to be of 
primary importance in atherosclerosis. This belief got him into a controversy with pathologist 
Carl von Rokitansky who thought the inflammatory changes were secondary. Recent 
research82 and modern investigations of Rokitanskys specimens83 however, appear to prove 
Virchow right. Atherosclerosis is now regarded as an inflammatory disease triggered by the 
accumulation of LDL in the arterial wall.  
The atherosclerotic lesion 
The normal artery wall is composed of three layers; the intima, the innermost layer which 
includes the endothelium and is separated from the other two by the internal elastic lamina, 
the media is the middle layer, consisting of smooth muscle cells (SMCs), and the adventitia is 
the outermost, connective tissue layer. Large arteries are supported by small vessels, the vasa 
vasorum, in the adventitia, which is where the nerves enabling vasomotor activity (dilation 
and constriction) are also located.  
A diffuse intimal thickening (DIT) seems to be a prerequisite for atherosclerosis.84 The first 
morphological change seen in early atherosclerosis is the fatty streak, an extracellular 
deposition of lipids in the outermost layer of DIT. LDL particles are retained in the 
extracellular matrix, where they are then oxidized, in response to elevated plasma levels of 
LDL.85, 86 LDL then releases phospholipids that activate the endothelial cells (ECs) into 
expressing leukocyte adhesion molecules such as VCAM-1.87 Leukocytes adhere to the 
endothelium and migrate into the intima in response to cytokines such as CX3CL1 
(fractalkine), CCL5 (RANTES) and CCL2 (MCP-1). Macrophage-colony stimulating factor 
(M-CSF) induces the differentiation of monocytes into macrophages, while scavenger 
receptors (SRs), such as CXCL16 and Toll-like receptors (TLRs) are upregulated on the cell 
surface. SRs mediate the uptake of oxidized LDL (oxLDL) particles by macrophages, turning 
them into foam cells. The TLRs initiate the activation of inflammation, which may result in 
the release of several vasoactive molecules, such as leukotrienes and nitric oxide (NO). SMCs 
are recruited from the media to the cap surrounding the lipid core, which, apart from SMCs, 
also contains a collagen-rich matrix. As the person ages and the disease becomes more 
advanced, fibrotic and calcific layers add to the plaque. Inside the plaque, the immune cells 
that are seen are predominantly macrophages and T-cells.88 Macrophages and vascular cells in 
a forming plaque produce CCL5 (RANTES), CXCL10 and CXCL11, all of which attract T-
cells. They also express CXCL16, and CCL11 - a mast cell attractant. Activated T cells 
differentiate into Th1 effector cells that produce interferon-γ (IFN-γ). IFN-γ in turn activates 
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macrophages and vascular cells, resulting in vascular inflammation that propagates 
atherosclerosis.80, 89, 90 The effect of plaque growth on the lumen diameter tends to be 
counteracted by the enlargement of the artery, usually referred to as Glagov´s phenomenon.91 
 
 
 
Figure 1. Evolution of atherosclerosis. a. EC dysfunction and activation under pro-
inflammatory conditions of hyperlipidemia leads to early platelet aggregation and leukocyte 
adhesion and increased permeability of endothelium. b. Monocytes accumulate lipids and 
transform into macrophages or foam cells, which results in fatty streaks. c. Apoptosis of 
macrophages and other plaque cells creates a necrotic core, and a fibrous cap that consists of 
matrix and an SMC layer forms. Neovascularization can occur within the plaque and from the 
adventitia, and leakage of fragile vessels can lead to plaque hemorrhage. d. Thinning and 
erosion of the fibrous cap in unstable plaques, for example, owing to matrix degradation by 
proteases, ultimately results in plaque rupture, with release of debris, activation of the 
coagulation system and plaque thrombosis of the artery. This leads to arterial occlusion and 
MI or stroke. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Immunology, Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte 
subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008;8:802-15, 
copyright 2008. 
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When a plaque ruptures or is eroded, platelets and the coagulation cascade are activated by 
substances inside the plaque and a thrombus is subsequently formed. As the thrombus grows 
or embolizes into narrower parts of the artery, the arterial occlusion causes ischemia, followed 
by the necrosis of dependent tissue. Since a large proportion of MIs are caused by plaque 
rupture,92 which in its turn is more affected by the vulnerability of the plaque than the size of 
the plaque or its effect on the lumen diameter, it is not easy to predict which plaques are 
potentially dangerous, at least not from imaging techniques alone. In sudden coronary deaths, 
approximately two-thirds of coronary thrombi are organizing, particularly in young 
individuals and in women.93 
Inflammation in cardiovascular disease 
Since the hypothesis that inflammation contributes to CV disease was first formulated, 
numerous publications have confirmed the relationship.79, 80, 94 There is also an association 
between CV disease and other inflammatory diseases; for example, the incidence of MI is 
increased in subjects with SLE,95 RA,96 gout97 and psoriasis.98 Heart rate variability, an 
independent predictor of mortality in ACS,99, 100 is inversely related with inflammatory 
markers in subjects with CV disease as well as in healthy subjects.101  
 
i. Immune system in atherosclerosis 
Inside the plaque, macrophages are the dominant cells, followed by T-cells. Neutrophils are 
few, suggesting chronic, not acute, inflammation. B-cells are also few in number, suggesting 
that humoral immunity is not important. CD4+ T-cells (CD4+ being a cell-surface glycoprotein 
that acts as a co-receptor for the T-cell receptor) help determine the extent – and nature – of 
the immune response, mainly through cytokine secretion. CD4+ T-cells coordinate and take 
part in the defense against external pathogens. Initially naive, the CD4+ T-cells differentiate 
into effector T-helper cells upon stimulation by antigen presenting cells (APCs). Cytokines 
determine if the T-helper cell will become type I (immunity against intracellular pathogens by 
secretion of interleukin-2, (IL-2), IL-12 and IFN-γ) or type 2 (clearance of extracellular 
pathogens and secretion of IL-4, IL-10 and IL-13). The cellular immune response to modified 
LDL antigen plays a crucial role in atherosclerosis. IL-10 and TGF-" exert anti-atherogenic 
effects. T-cells promote atherogenesis. In a plaque, about 40% of cells express macrophage 
markers, 10 % are CD3+ T-cells, while the rest mostly appear to be SMCs, even if small 
numbers of B-cells, DCs and mast cells have also been demonstrated. 80, 81, 102, 103  
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The inverse correlation between HDL levels and the risk of CHD is well documented. The 
anti-atherogenic effect of HDL can be attributed to its ability to remove cholesterol by 
cholesterol efflux from foam cells, as well as SMCs and ECs inside the arterial wall. 
Infiltration of the atherosclerotic plaque by macrophages and activated T-cells lead to matrix 
degradation, apoptosis of cells in the arterial wall and to increased production of pro-
inflammatory cytokines, all increasing the risk of plaque rupture. 85, 104  
 
Cytokines are small protein molecules that are secreted by a variety of cells in response to 
stimuli such as apoptotic cells, bacterial endotoxins and other cytokines. They usually act 
over short distances in a paracrine, juxtacrine or autocrine way. When expressed strongly in 
abundance, however, cytokines may spill over into the circulation and exert endocrine effects.  
Chemokines are chemotactic cytokines, a large protein family whose common denominator is 
their influence on leukocyte chemotaxis. They are small proteins, typically 8-14 kDa, that act 
via chemokine receptors. Quite often, the same chemokine has been “discovered” by several 
research groups and ended up with several names. To bring order to this chaos, a consensus 
agreement was reached, dividing chemokines into four subfamilies. C, CC, CXC and CX3C 
(based on the identification of a conserved cystine residue pattern).  
 
ii. Circulating inflammatory markers 
A number of inflammation-related substances are present in the circulating blood and can be 
analyzed by immunometric techniques. Some, particularly C-reactive protein (CRP), have 
been studied in detail. The circulating levels of proinflammatory cytokines are increased in 
patients with ACS and in HF, where circulating levels correlate with functional class.105-108 
This thesis evaluates the prognostic power of one representative of the tumor necrosis factor 
(TNF)-superfamily (osteoprotegerin, OPG), another from the CXC cytokine subfamily 
(CXCL16), as well as a granin (chromogranin A, CgA) with metabolites active in 
communication between the neuroendocrine and immune systems.109 
 
C-reactive protein (CRP) was the first acute-phase protein to be described. It was found in 
sera from patients acutely ill with lobar pneumonia and was named for its ability to precipitate 
C-polysaccharide of Streptococcus pneumoniae.110 It is synthesized in hepatocytes111 in 
response to inflammatory cytokines, particularly IL-6, with or without the support of IL-1.112, 
113 CRP belongs to the pentraxin protein family, which is usually divided into two subfamilies 
based on size: the short pentraxins to which CRP belongs are 25 kDA while the long 
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pentraxins typically are 40-50 kDa. In atherosclerosis, IL-6 and IL-1, the cytokines that 
stimulate CRP production, are produced by macrophages in transition to foam cells. 
Originally rather crude, tailored as they were to being used in infections, the assays for CRP 
have been fine tuned into the highly sensitive (hs-)CRP, available today. Hs-CRP detects even 
mild inflammation, from values nearing zero up to 10 mg/L. Since CRP was shown to predict 
CV risk in patients with manifest atherosclerosis,114-116 as well as in healthy subjects,117 
several studies have attempted to figure out whether CRP in itself could be pro-atherogenic118, 
119 or is merely an innocent bystander in vascular disease. The data suggest that CRP may 
have effects on plaque stability, endothelial function, coagulation, fibrinolysis and LDL 
oxidation. 
The fact that several Mendelian randomization studies have failed to demonstrate 
concordance between CRP genotypes, CPR concentrations and CV risk has been used as an 
argument against causality and a recently published paper by Elliot et al.120 
contradicts a causative role.  
 
In 1997, Ridker with coworkers showed that prophylactic treatment with salicylic acid, an 
inhibitor of both platelet aggregation and inflammation, is more effective in subjects with 
higher CRP levels117 and they went on to demonstrate that rosuvastatin lowered CRP levels – 
and the risk of MI by 54% – in subjects with normal lipids but elevated CRP. The latter 
finding was deemed interesting enough to make no 2 on TIME Magazine’s “Top 10 medical 
breakthroughs” list for 2008.  
 
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF), is a 
basic secretory glycoprotein that consists of 401 amino acid residues with 7 distinct structural 
domains. It exists in two forms: the monomeric one has a molecular weight of 60 kD, while a 
homodimer linked by a disulfide bond also exists121 and is biologically more active. Amino 
terminal domains 1-4 are cysteine rich and have osteoclastic inhibitory properties, while, at 
the carboxy-terminal end, domains 5-6 have apoptosis-mediating death domain-homologous 
regions and domain 7 has a free cysteine residue (enabling disulfide bond and hence 
dimerization) and a heparin-binding region.122 
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Figure 2. The RANKL-OPG-RANK axis is illustrated schematically within the vessel wall. 
A. Regulation of osteoclastogenesis: Soluble and membrane bound RANKL on osteoblasts 
stimulate: 1. proliferation into preosteoclasts 2. differentiation into prefusion osteoclasts 3. 
fusion into multinucleated osteoclasts that resorb bone, and 4. prevent apoptosis of mature 
osteoclasts. B. OPG blocks the effects of RANKL by preventing binding to its receptor 
RANK. Proinflammatory cytokines upregulate RANKL on 1. ECs 2. activated T cells 3. 
vascular (V-)SMCs undergoing osteogenic differentiation and 4. ECs in contact wih CD-44-
expressing VSMCs. C. Function of RANKL in atherosclerotic vascular calcification. RANKL 
may play a role in the atherosclerotic process through: 1. triggering EC survival and 
proliferation 2. stimulating monocyte and lymphocyte transmigration and activation of T cells 
3. maturation and activation of dendritic cells (DCs) 4. increased matrix MMP activity from 
monocytes and VSMCs that may promote plaque rupture and thrombus formation, and 5. 
promotion of osteogenesis, leading to synthesis of bone proteins and matrix calcification. 
Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler 
Thromb Vasc Biol 2010;30:1684-6. Reprinted by permission. 
 
OPG is a soluble decoy receptor for two members of the TNF receptor superfamily, RANKL 
(receptor activator of nuclear factor-kappaB ligand) and TRAIL (tumor necrosis factor-related 
apoptosis-inducing ligand). By binding RANKL it can inhibit the interaction between 
RANKL and RANK.123 It also has more classical cytokine effects. ECs, vascular SMCs and 
osteoblasts express OPG, which is colocalized with von Willebrand factor within secretory 
granules called Weibel-Palade bodies inside ECs.124 RANK is expressed on the surface of 
osteoclasts, monocytes and DCs, while RANKL is expressed on osteoblasts, T-cells and 
stromal cells.  
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OPG inhibits vascular calcification in mice and, like RANKL, it is an important regulating 
molecule in bone turnover; it inhibits osteoclastogenesis by binding RANKL. Paradoxically, 
in clinical studies, it appears that serum OPG levels increase with the progression of CAD125 
and are related to coronary artery calcium and aortic plaque,126 the number of plaques,127 as 
well as being increased in STEMI128 and UAP.129 OPG is also detected in human 
atherosclerotic lesions.130 In the general population, OPG levels are associated with CV risk 
factors and atherosclerotic plaque burden, and predict plaque growth in women but not in 
men.131 Elevated circulating levels are associated with the increased prevalence and severity 
of coronary artery disease, CV disease and peripheral vascular disease. In a nested case-
control study of 254 patients with ischemic stroke and 254 controls within a prospective 
cohort of 57053 Danish men and women who had OPG drawn at baseline, no association was 
found between OPG plasma concentrations and the risk of ischemic stroke.132 OPG is 
elevated in type II diabetics with microvascular complications. OPG perhaps regulates 
RANKL-mediated extracellular matrix remodeling (e.g. in myocardium in HF development 
and in atherosclerotic plaques).  
 
In a study of post-MI HF patients, elevated OPG concentrations were associated with an 
increased risk of death, even after correction for BNP. Further, the prognostic value of OPG 
in relation to both all-cause mortality and CV events was actually stronger at one month and 
one year after inclusion than that of the baseline value.133 In patients with severe aortic 
stenosis, with or without HF, Helske et al. demonstrated increased OPG levels in HF due to 
LV pressure overload that decreased after successful valve replacement.134 In stable HF 
patients, OPG levels are associated with mortality, independently of conventional CV risk 
factors.135 
 
Most animal studies support a protective role for OPG in the vasculature. OPG-deficient mice 
develop vascular calcifications.136 Bone loss in oophorectomized mice was prevented by 
OPG.137 Transgenic mice that overexpress OPG develop osteopetrosis.  
Osteoporosis appears to be related to atherosclerosis, especially vascular calcification, in 
elderly people, postmenopausal women and persons with autoimmune disease. It has been 
suggested that OPG could be the link between bone metabolism and vascular calcification 
that explains this relationship, but data exist that argue against.138, 139 
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Table 1. The OPG/RANK/RANKL/TRAIL axis 
 
CXCL16 is a cytokine that combines chemokine functions with those of an SR and an 
adhesion molecule. Also known as SR-PSOX (SR for phosphatidylserine and oxidized 
LDL/lipoprotein), it is a chemokine involved in inflammation, lipid metabolism and matrix 
degradation that is expressed by T-cells, macrophages, DCs, ECs and cytokine-stimulated 
SMCs. CXCL16 is different in that it has a mucin-like stalk, as well as cytoplasmic and 
transmembrane domains that are not present in other CXC chemokines. It is cleaved off from 
the cell membrane by ADAM10,140, 141 a disintegrin and metalloproteinase, and the 
chemokine domain of the released protein functions as a chemoattractant for cells bearing its 
specific receptor, CXCR6 or Bonzo, ie T, NK, NKT, B and DCs.142, 143 CXCL16 is 
upregulated in macrophages in response to atherogenic lipids and, by acting as an SR for 
oxLDL,144 it aids the transition from macrophages into foam cells. It works as a 
chemoattractant for SMCs and also stimulates their proliferation and transition into foam cells 
and has pro-inflammatory effects.145 CXCL16 is present in both human and murine 
atherosclerotic plaques and is upregulated by IFN-γ.146 Sheikine et al. found significantly 
lower levels of CXCL16 in 40 patients with stable angina than in a healthy control group and 
saw a (non-significant) tendency towards lower levels in 17 UAP/NSTEMI patients and 387 
survivors of a first MI before the age of 60 compared with healthy subjects.147 Mitsuoka et al. 
found that CXCL16 was lower in ACS than in stable angina patients undergoing coronary 
angiography148, but the study had few (17) ACS patients and non-ACS (89) patients. These 
studies had fewer subjects and follow-up was shorter than in our study, and some published 
data contradict their findings. In a nested case-control study of acute and chronic CAD, 
circulating levels were associated with chronic CAD and ACS after adjustment for established 
risk factors including CRP.149 In another study, even though no significant differences were 
 OPG  RANK RANKL TRAIL 
     
Produced by ECs, VSMCs, 
osteoblasts 
Osteoclasts, 
monocytes, DCs 
T-cells, stromal 
cells, osteoblasts 
Normal organs and 
tissues, cancer cells 
 
Actions Decoy receptor for 
RANKL and TRAIL 
Receptor  
for RANKL 
Activates osteoclasts Membrane bound 
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receptors DR4 and 
DR5 
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seen between acute and stable CAD, CXCL16 levels were significantly higher in CAD 
patients.150  
 
 
 
Figure 3. CXCL16 in the vessel wall. Membrane bound CXCL16 1. is upregulated on 
macrophages in response to atherogenic lipids 2. acts as an SR for oxLDL, aiding the 
transition of macrophages and SMCs into foam cells 3. attracts cells bearing its specific 
receptor, CXCR6, eg. SMCs and monocytes 4. is shedded, in its soluble form, by ADAM10. 
Original illustration by Thor Ueland. 
 
Increased serum levels of CXCL16 have been demonstrated in patients with cardiomyopathy-
induced HF in whom its expression is also upregulated in the cardiomyocytes151, suggesting a 
possible role in HF development. Vascular SMCs that are stimulated with CXCL16 show 
enhanced MMP expression, suggesting that CXCL16 could have matrix-degrading 
properties.150 
 
Chromogranin A is a 49 kDa acidic polypeptide and a member of the granin family, eight 
proteins, CgA-C, SgIII-VI and VGF, all of which are found as major components of the 
soluble core of dense-core secretory granules in neuroendocrine cells throughout the body. 
The granins range from 27 to 100 kDa in size and function as pro-hormones, giving rise to 
diverse biologically active peptide fragments with an array of effects on the vascular system 
and the heart, for example. From CgA, catestatin, parastatin, pancreastatin, vasostatin and 
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chromasin – to mention a few – can be cleaved off and have antibacterial and antifungal 
effects, activate the adhesion of fibroblasts, the relaxation of constricted vessels and the 
reduction of intracellular calcium. Catestatin has antimalarial as well as antimicrobial effects 
and induces chemotaxis. It appears that CgA – or rather a cleaved-off peptide from CgA – 
promotes the generation of secretory vesicles and possibly controls sorting152. CgA is co-
secreted with peptide hormones and amines such as noradrenaline. In healthy subjects, the 
serum levels of CgA are, however, not related to circulating levels of norepinephrine and 
epinephrine153. CgA levels are markedly elevated in neuroendocrine tumours (NETs), such as 
pheochromocytoma154, carcinoid155 and neuroblastoma156. It is therefore a frequently used 
marker of activity in different kinds of NETs and is also considered to be the best available 
biomarker for the diagnosis of NETs. As opposed to the catecholamines, with a half-life in the 
circulation of just a few minutes, CgA is fairly stable. In an animal model of secondary 
hypertension, CgA levels were elevated 157, a finding that is corroborated by observations in 
humans.157 CgA levels are also more likely to be elevated in inflammatory diseases such as 
rheumatoid arthritis,158 Crohn´s disease and ulcerative colitis.159 
 
The circulating levels of CgA are strongly influenced by renal function – patients with renal 
failure have been shown to have levels up to 22 times those of healthy subjects and patients 
with liver cirrhosis also have increased levels160. Proton pump inhibitors increase the levels of 
chromogranin A substantially161. Levels also increase with age. Chromogranin A is produced 
by human endocardium in patients with cardiomyopathy but not in controls and exerts 
negative inotropic effects on mammalian heart162 and predicts mortality post-MI163, 164 but not 
in stable HF patients after adjustment for clinical risk markers165. Levels are increased in HF 
and also correlate with the severity of HF with levels in NYHA class IV patients as high as 
those seen in pheochromocytoma and other neuroendocrine tumors.166 CgA is believed to 
reflect neurohormonal activation and to provide a link between sympathetic tonus and 
inflammation.  
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Rationale 
 
We hypothesized that OPG, CXCL16 and CgA could add valuable information on the 
prognosis in ACS concerning mortality and morbidity due to  
• their presence in failing myocardium 
• the elevated circulating levels seen in patients wih HF  
• the possible role of OPG and CXCL16 in atherosclerosis and plaque destabilization 
• the presence of CgA in neurohormonal activation 
They are all easy to quantify in a clinical context, which makes them suitable biomarker 
candidates.  
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Aims 
 
The overall aim of this thesis was to study the feasibility of using some different biochemical 
markers, all supposedly involved in inflammation, for prognostication in ACS. We sought to 
evaluate the prognostic merit of OPG, CXCL16, a combination of OPG and CXCL16 and 
CgA in patients hospitalized due to an acute MI or UAP. 
 
• To assess OPG, CXCL16 and a combination of the two as markers of mortality in 
ACS patients  
• To evaluate OPG, CXCL16 and a combination of the two for predicting 
rehospitalizations due to HF, MI and stroke in ACS patients  
• To examine whether baseline values of CXCL16 and OPG are equally predictive of 
mortality and morbidity as levels obtained in direct relationship to an ACS 
• To describe the pattern of serum concentrations of OPG and CXCL16 after an ACS 
• To examine the association between CgA and mortality and rehospitalizations in ACS 
 
 
 
    
 
Methods 
Study population and data collection 
 
 
Figure 4. Proportions of index diagnoses in PRACSIS. 
 
Patients admitted to the coronary care unit (CCU) at Sahlgrenska University Hospital, 
Gothenburg, Sweden from September 1995 to March 2001 with an ACS, i.e. a diagnosis of 
UAP, NSTEMI or STEMI were eligible for prospective inclusion in PRACSIS, Prognosis and 
risk in acute coronary syndrome in Sweden, Figure 4. 
The main exclusion criteria were age < 18 or ! 80 years, non-coronary artery disease 
associated with an expected life expectancy of < 1 year, residence outside the hospital’s 
catchment area, unwillingness to participate and prior admission resulting in inclusion in the 
study. During the inclusion period (5.5 years), 2335 patients were included in the PRACSIS 
program. Until November 1995, only clinical information was recorded and no consecutive 
blood sampling was performed. From then on, blood was drawn on the first morning in the 
CCU in patients who had, by then, received a diagnosis of MI or UAP. Serum was then 
frozen at -70° for later analysis. Of the patients included in PRACSIS, 612 were transferred to 
the CCU from either an internal medicine ward (usually after having been admitted there due 
to uncertainty about the ACS diagnosis) or from the intensive care unit (where they had been 
admitted due to a need for mechanical ventilation). For logistical reasons, the majority of 
these 612 patients did not have blood sampled in the morning. During some weekends, no 
blood collection was possible even though patients were included and, finally, some patients 
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were undergoing angiography on, or died prior to, the first morning. These patients were 
enrolled in the PRACSIS program but were not included in the biomarker substudy.  
A diagnosis of ACS had to be supported by ECG changes (defined below) on admission, 
cardiac biomarkers increased above the upper reference levels (CK-MB above 5 µg/L or 
troponin T above 0.04 µg/L) or previously recognized coronary artery disease such as MI, 
prior coronary artery bypass grafting (CABG) or prior percutaneous coronary intervention 
(PCI), prior angina pectoris with significant changes on coronary angiography or a stress test 
suggestive of ischemia.  
ECG changes were defined as  
* ST elevation ≥ 0.1 mV (0.2 mV in V1-V4) or  
* ST depression ≥ 0.1 mV or  
* T-wave inversion in at least two adjacent leads 
* Q-wave ≥ 0.03 sec and ≥ 25% of the amplitude of the following R-wave 
* LBBB 
 
The inclusion criteria as stated on the inclusion form were: 
1) Patients ≤ 79 years receiving thrombolysis or PCI due to a certain or uncertain 
diagnosis of MI; included on arrival 
2) Patients ≤ 79 years with a suspected MI who were not being treated with thrombolysis 
or PCI and patients ≤ 79 years with suspected UAP. Included when the criteria below are 
met.  
 
Symptoms 
a) Accelerating angina upon exertion during the last four weeks 
b) Angina at rest during the last four weeks but not the last 48 hours 
c) Angina at rest during the last 48 hours 
 
Objective findings 
a) Elevation of CK-MB or troponin after admission 
b) New ST depression or T-wave inversion at admission or during hospitalization 
c) ST depression on exercise ECG before hospital discharge 
d) Previous objective evidence of ischemic heart disease such as previous MI, 
pathological exercise ECG, pathological coronary angiography 
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Patients below the age of 75 years received an invitation to an outpatient follow-up visit 3 
months after discharge. Those who accepted had blood drawn on this visit as well as 
completing the Cardiac Health Profile, a disease-specific quality of life questionnaire. 167 
Echocardiography 
An echocardiographic investigation was performed by an experienced investigator within 5 
days of hospital admission. The biplane LVEF was calculated by the disc sum method and 
tracings were checked in the motion mode for accuracy. 
Blood sampling procedures 
Peripheral venous blood was obtained within 24 hours of admission and on an outpatient visit 
approximately 90 days after the index admission by direct venipuncture of an antecubital vein 
after the patients had been resting for at least 30 minutes. Blood samples for OPG, CgA and 
CXCL16 determination (serum) were drawn into serum tubes and centrifuged at room 
temperature within 1 hour. Blood samples for the determination of CRP and BNP/proBNP 
(plasma) were drawn into pyrogen-free tubes with EDTA as the anticoagulant, immediately 
immersed in ice water and centrifuged at -4° within 1 hour. All plasma and serum samples 
were stored at -70°C and thawed < 3 times prior to analysis.  
Biochemical analysis 
Both serum OPG and plasma CXCL16 were quantified by an enzyme immunoassay using 
commercially available matched antibodies (R&D Systems, Minneapolis, MN). The intra- and 
interassay coefficient of variation was 3.6% and 10.6% for OPG and the intraobserver 
coefficient of variation for CXCL16 was 3.3 ± 2.2% (mean±S.D.). The sensitivity for OPG, 
defined as ±3 SD of the 0 standard, was determined as 15 pg/mL and the detection limit for 
CXCL16 was calculated as 11 pg/mL. CgA was measured by a commercially available 
ELISA assay (DakoCytomation, Glostrup, Denmark). The detection limit of the assay was 7.0 
U/L and the intra- and interassay coefficients of variation were < 5% and 10% respectively. 
According to the manufacturer, the upper limit is 18 U/L. Troponin T (TnT) and creatinine 
kinase MB (CK-MB) fractions in serum were measured on a modular platform (Roche 
Diagnostics, Mannheim, Germany). CRP, TnI, BNP and proBNP3-108 were measured using 
immunofluorescent assays calibrated with spiked plasma (Biosite Inc, San Diego, CA). CRP 
for paper III was quantified in Oslo, Norway by an enzyme immunoassay using commercially 
available matched antibodies (R&D Systems, Minneapolis, MN). Samples for CRP analyses 
were diluted (factor 1600) in order to bring the concentration into the measurable range. The 
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minimal detectable concentration – upper range was 400-30,000 pg/mL for proBNP, and 0.3-
100 mg/L for CRP. All samples were run in duplicate in a blinded fashion. Creatinine and 
total cholesterol concentrations in serum were determined by routine laboratory methods.  
 
Table 2. Coefficient of variation for the studied biomarkers 
  OPG CXCL16 CgA 
Detection limit 15 pg/mL 11 pg/mL 
7.0 
U/L 
Intraassay CoV 3.6%  <5% 
Interassay CoV 10.6%  <10% 
Intraobserver CoV  3.3±2.2%  
CoV freeze-thaw x 3  3.9±3.7%  
CoV circadian variation  8.8±3.0%  
CoV food intake   9.7±3.9%   
 
 
Assessment of endpoints 
The primary outcome measure was all-cause mortality. Survival confirmation and date of 
death were obtained from the Swedish National Population Registry. Patients who emigrated 
from Sweden and were lost to follow-up were censored alive on the day of emigration. For 
the papers on CXCL, CgA and on the OPG and CXCL combination, a total of 11 patients 
were lost to follow-up due to emigration. In the smaller OPG study, 5 of the emigrated 
patients were included.  
Secondary outcome measures were the incidence of acute MI (International Statistical 
Classification of Disease, Ninth Revision (ICD-9) code 410 or ICD-10 code I21 or I22), HF 
(ICD-9 code 428 or ICD-10 code I50) and stroke (ICD-9 codes 431, 432, 433, or 436 or ICD-
10 codes I61, I62, I63, or I64), as obtained from the Swedish Hospital Discharge Registry, 
and CV mortality (ICD-9 codes 390-459 or ICD-10 codes I00-I99), as obtained from the 
Swedish National Cause of Death Register. In study I, II and IV, we used the endpoints all-
cause mortality (long-term) and rehospitalization due to HF, MI or stroke. In study III, we 
studied all-cause and CV mortality and rehospitalization due to HF or MI, since we had 
already concluded that neither OPG nor CXCL16 was predictive of stroke rehospitalization.  
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Potential confounders 
 
Patients were prospectively classified according to maximum Killip class on admission and 
during the index hospitalization. Electrocardiographic findings on admission were classified 
according to the presence or absence of ST-segment elevation and ST-segment depression. 
Presenting signs and symptoms, biochemical variables, medical treatment and procedures and 
in-hospital complications were recorded. Based on hospital records and personal interviews, 
patients were classified as having or not having a history of MI, angina pectoris, HF, diabetes 
mellitus, hypercholesterolemia or arterial hypertension. The GFR in ml/min was estimated 
using the Cockcroft-Gault formula [(140-age) x weight (kg)/serum creatinine (umol/L)] 
multiplied by a constant of 1.23 in men and 1.04 in women.  
 
Table 3. Variables adjusted for in the studies 
  Paper I Paper II Paper III Paper IV 
Variables adjusted for  OPG  CXCL16 CXCL16 OPG  CgA 
Age x x x x 
Gender x x  x 
Index diagnosis x x  x 
Prior hypertension x x  x 
Prior CHF x x x x 
Prior diabetes x x  x 
Prior angina x x  x 
Prior MI x x x x 
Smoking status x x  x 
     
ST-depression   x  
Heart rate x x x x 
Systolic BP   x  
Killip class (>1) x x  x 
No in-hospital PCI   x  
     
Est. GFR x x  x 
Baseline creatinine   x  
Elevated cardiac markers   x  
Peak CK-MB x x  x 
TnI x    
TnT  x  x 
CRP x x x  
Pro-BNP  x x x 
BNP x    
LVEF x x x x 
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Ethics 
Informed consent was obtained from all individuals. The study protocol was approved by the 
Regional Ethics Committee at the Sahlgrenska Academy, Gothenburg University. 
 
Statistical analysis 
We used 95% confidence intervals to indicate the precision of estimated HRs. 
The Mann-Whitney U test was used to test the associations between the different markers 
and the dichotomous baseline demographic variables and the CV risk factors. 
Spearman’s rank correlation statistics were used to determine the association between the 
markers and continuous variables.  
Fisher’s exact test was used in Paper III to test any difference between the four different 
combinations of OPG and CXCL16 quartiles and the dichotomous baseline demographic 
variables and the CV risk factors. 
The Kruskal-Wallis test was used in Paper III to test any difference between the four 
different combinations of OPG and CXCL16 quartiles and continuous variables. 
Wilcoxon’s signed rank test was used in Paper III for paired testing, i.e. the difference in 
marker levels between time points.  
Pearson’s correlation was used to examine the extent to which different variables were 
related.  
Cox proportional hazards regression analysis was used to calculate crude and adjusted risk 
estimates associated with a 1-SD increase in logarithmically transformed CXCL16 levels for 
the different endpoints. In the multivariate analyses, we adjusted for the potential 
confounders, using the same set of variables previously described in Papers I, II and IV and 
the GRACE score variables in Paper III. 
Kaplan-Meier curves were generated to visualize the relationship between the markers in 
quartiles (in Paper III, we used the four quartile combinations OPG q4/CXCL16 q4, OPG 
q4/CXCL16 q1-3, OPG q1-3/CXCL16 q4, OPG q1-3/CXCL16 q1-3) and mortality.  
The log-rank test was used for comparisons of the resulting curves.  
C-statistics were used for exploring the sensitivity and specificity of the different markers in 
predicting mortality. C-statistics equal the “area under curve”, AUC, in receiver operating 
characteristic (ROC) curves, i.e. they are a measure of model discrimination for binary 
outcomes. 
   
 
 
Results 
Study I 
In the first paper, we examined circulating OPG concentrations in a population of 897 patients 
for whom we also had data on CRP, BNP and TnI in addition to clinical risk predictors. The 
median age was 66 years and 29% of the patients were female. During a follow-up period of 
89 months, 261 patients (29%) died. Patients with higher OPG levels were more likely to be 
older and to have a lower body mass index. OPG levels were associated with a previous 
history of HF but not with prior MI. Higher OPG levels were associated with a number of 
indices of acute thrombotic occlusion, myocardial damage and LV dysfunction, such as ST-
segment elevation, treatment with thrombolysis/primary PCI, CK-MB and TnI, acute signs of 
HF and LVEF. Serum levels of OPG were strongly associated with long-term all-cause 
mortality and the development of HF, irrespective of the index diagnosis. The hazard ratio 
(HR) per 1 SD pg/mL increase in the natural logarithm of OPG were significant for mortality 
and HF, and remained so after adjustment for clinical variables, BNP, CRP and TnI (Table 4). 
These associations remained even including LVEF (hazard ratio for mortality 1.4; 95 % CI 
1.2-1.7; p < 0.0001 and for HF 1.6; 95% CI 1.2-2.1; p < 0.0001). According to univariate 
analysis, the baseline OPG concentration was associated with the recurrence of MI but not 
after adjustment for confounders.  
In a cohort of 724 of the patients, echocardiographic determination of LVEF had also been 
performed and after further adjustment for LVEF, OPG was still predictive of mortality and 
HF development. C-statistics showed that OPG provided significantly better prognostic 
information: AUC 0.68 (95% CI 0.64-0.73) than TnI: AUC 0.55 (95% CI 0.50-0.60), p < 
0.001 and CRP: AUC 0.59 (95% CI 0.54-0.63), p = 0.002) and was of similar value to BNP: 
AUC 0.70 (95% CI 0.66-0.74), p = 0.28) and LVEF: AUC 0.71 (95% CI 0.66-0.76), p = 0.09.  
 
Table 4. Associations between OPG concentrations and events during follow-up 
OPG Unadjusted   Adjusted    
 HR (95% CI) P value HR (95% CI) P value 
Mortality 1.7 (1.5-1.9) <0.0001 1.3 (1.1-1.5) 0.0003 
HF 2.0 (1.6-2.5) <0.0001 1.6 (1.2-2.1) 0.0002 
Recurrent MI 1.3 (1.0-1.5) 0.02 1.0 (0.8-1.3) 0.70 
Stroke 1.2 (0.9-1.6) 0.35 0.9 (0.6-1.3) 0.61 
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Figure 5. OPG and long-term mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. C-statistics for OPG and other markers, Paper I. 
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Study II 
 
CXCL16 levels were assessed in 1351 patients, 377 of whom died during a median follow-up 
of 81 months. Patients with higher levels of CXCL16 were more likely to be older, to be 
female, to have a history of hypertension and to be current smokers. There was no significant 
association between CXCL16 and prior history of MI or HF. Higher CXCL16 levels were 
associated with STEMI and variables related to acute myocardial injury, such as CK-MB, 
TnT, thrombolysis, Killip class and LVEF. CXCL16 predicted long-term mortality and the 
relationship remained after adjustment for clinical and laboratory risk markers CRP, TnT and 
proBNP as well as index diagnosis and LVEF. Those with 4th quartile levels were 3 times as 
likely as those with 1st quartile levels to be hospitalized due to HF and twice as likely to be 
rehospitalized due to MI. After adjustment for clinical risk factors, the associations were still 
significant. However, after further adjustments were made for LVEF, CRP, proBNP and TnT, 
in a subgroup (n= 714) where these data were available, there was no remaining association 
between CXCL16 levels and readmission for MI or HF. When analyzing data for subgroups, 
we found a significant association between CXCL16 levels at inclusion and prognosis in 
patients with STEMI undergoing thrombolysis and primary PCI, as well as in non-ST-
elevation ACS not undergoing revascularization. This association remained significant after 
adjustment for clinical variables and, in the non-ST elevation ACS group not undergoing 
revascularization, also after adjustment for LVEF, TnT, pro-BNP and CRP. In STEMI, as 
well as in non-ST-elevation-ACS, a univariate association was seen between baseline 
CXCL16 levels and prognosis, but it was attenuated after further adjustments. 
We found a significant interaction between CXCL16 and CRP even though CXCL16 
predicted mortality after adjustment for CRP. Having 4th quartile levels of CXCL16 but not 
of CRP gave an HR of 1.4 (95 % CI 1.0-1.9), p = 0.06, which was of the same order as the 
HR of having 4th quartile levels of CRP but not of CXCL16, 1.6 (95% CI 1.1-2.2), p = 0.005, 
when compared with patients with neither CXCL16 nor CRP in the 4th quartile. A 
considerably higher HR was noted for patients with both markers in the 4th quartile, 3.3 (95% 
CI 2.3-4.6), p < 0.0001.  
 
We observed a high stability of CXCL16 with little variation after three cycles of freezing and 
thawing, minor circadian variation and little effect of food intake on serum levels. We also 
compared the mean and median CXCL16 levels from the first half of the study inclusion 
period with the second half, with neither showing a difference over time.  
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Table 5. Associations between CXCL16 concentrations and events during follow-up. 
CXCL16 Unadjusted   Adjusted    
 HR (95% CI) P value HR (95% CI) P value 
Mortality 1.33 (1.21-1.46) <0.0001 1.21 (1.09-1.36) 0.0006 
HF 1.31 (1.12-1.52) 0.0005 1.25 (1.05-1.48) 0.01 
Recurrent MI 1.25 (1.08-1.44) 0.002 1.18 (1.01-1.38) 0.04 
Stroke 1.09 (0.86-1.39) 0.48 0.98 (0.77-1.25) 0.89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CXCL16 and long-term survival, Paper II. 
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Study III 
 
A combination of OPG and CXCL16 for risk prediction was assessed in 1322 patients, 30 % 
of whom were female and the median age was 67 years. During the first 3 months of follow-
up, 110 patients, i.e. 8.3% died, 34 (2.6%) during the index hospitalization. All the deaths 
were from CV causes. During the same period 223 patients developed HF, 198 of them during 
index hospitalization, and 75 patients had new MIs, 18 during index hospitalization. Using 
patients with both OPG and CXCL16 in quartiles 1-3 as a reference, having 4th quartile levels 
of both markers was associated with an almost fivefold increase in total mortality and, after 
adjustment for the GRACE score, a threefold mortality increase remained and was significant. 
Developing HF was approximately four times as likely in those with the highest OPG and 
CXCL16 levels and, after adjustment for the GRACE score, almost three times as likely as in 
those with the lower quartiles of both. There was, however, no association between high 
levels and new hospitalizations due to MI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. 3-month morbidity and mortality, Paper III 
   
The median, (25th, 75th percentile) total follow-up period was 91 months (70, 110 months). 
During that period, there were 411 deaths (31% of patients), of which 287 were from CV 
causes, while 329 patients were hospitalized with HF and 235 with acute MI.  
 635 patients also had OPG and CXCL16 sampled at 3 months after the index admission.  
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Figure 9. HR for quartiles 4 
of CXCL16 and OPG and 
events during follow-up. 
 
Study IV 
 
The CgA concentration was available in 1268 patients. 389 patients (31%) died during 
follow-up (median 92 months). Patients with higher CgA levels were more likely to be older, 
to have a lower body mass index and to be on treatment with diuretics, angiotensin-converting 
enzyme blockers, angiotensin receptor blockers, statins or salicylic acid. CgA was also 
associated with a history of MI and HF as well as acute signs of HF and a low LVEF, but not 
with any variables related to the acute infarct process. Patients with higher CgA levels were 
also more likely to have a low GFR and a significant correlation between GFR and CgA was 
seen (Rs = -0.43, p < 0.001). No gender-related differences were seen. Since no significant 
interaction was found between index diagnosis and CgA in terms of outcome, we did not 
analyze the data for subgroups. CgA predicted mortality and hospitalizations for HF after 
adjustments for conventional risk factors, including TnT, with HR 1.27 (1.13-1-42), p < 
0.001, for mortality and HR 1.23 (1.01-1.49), p = 0.04, for HF hospitalizations. After further 
adjustment for LVEF and proBNP, CgA was still predictive of mortality, 1.18 (95% CI 1.01-
1.37), p < 0.04. CgA predicted recurrent MI in univariate analysis but the association was 
attenuated and no longer significant after adjustment for clinical risk factors. However, an 
independent association between CgA and recurrent MI was found in the subgroup where 
TnT was available. We also assessed the relationship between CgA and stroke but found no 
significant associations even in univariate analysis.  
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Table 6. Associations between CgA concentrations and events during follow-up 
CgA Unadjusted   Adjusted    
 HR (95% CI) P value HR (95% CI) P value 
Mortality 1.57 (1.44-1.70) <0.001 1.28 (1.15-1.42) <0.01 
HF 1.54 (1.35-1.76) <0.001 1.24 (1.04-1.47) 0.02 
Recurrent MI 1.27 (1.10-1.47) <0.001 1.15 (0.96-1.36) 0.12 
Stroke 1.16 (0.93-1.46)    0.19 0.96 (0.73-1.26) 0.76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. CgA and long-term survival. 
 
 

   
 
General discussion 
   
The prognosis for people developing ACS varies a great deal; some patients will not leave the 
hospital alive, others die within a few months and some can look forward to decades of life in 
good health. PRACSIS was conceived to study predictors of prognosis in a consecutive series 
of ACS patients. This thesis focused on the study of three biochemical markers and their 
relationship with prognosis relating to both mortality and CV morbidity.  
 
Methodological considerations 
PRACSIS comprises a prospective, single-center cohort of ACS patients. A prospective 
design usually entails several advantages compared with a retrospective design; sources of 
bias and confounding are generally fewer. In Sweden, all citizens have a personal 
identification number, the national registration number, based on the year, month and date of 
birth combined with four digits at the end that make the number unique to the individual. All 
deaths are reported, using this number as a unique identifier, to the Swedish National 
Population Registry. In our study, only 11 patients were lost to follow-up, all of them due to 
emigration. All hospitalizations are recorded with diagnoses in the Swedish Hospital 
Discharge Registry, again using the national registration number. This is a strength of all 
clinical research in Sweden, as it enables an almost complete follow-up at least of mortality 
(with the exception of those who emigrate during follow-up) and probably does fairly well 
concerning hospitalizations in Sweden even though Swedish people travel quite a lot – in 
2009, 6.8 million trips abroad were made by the 9.3 million population of Sweden.168  
 
Did we use the optimal time point for blood sampling of the markers in ACS? When it comes 
to OPG, there are data that suggest that OPG is elevated as early as 1 hour into an ACS.128 
Since many patients present more than 1 hour after symptom onset and more time passes 
before blood can be sampled, obtaining OPG levels before a possible increase caused by an 
ACS is not feasible. An alternative approach in the study of risk prediction is population 
studies as exemplified by the Framingham cohort, where OPG in the general population 
predicted future events.169 In this case, several years can elapse between blood sampling and 
event, and we do not know the OPG level in direct connection with the event. At any rate, as 
we have demonstrated in Paper III, there is little change from day 1 to day 4, suggesting there 
may be a window of opportunity for sampling OPG at least during the first four days. 
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Regarding CXCL16, the variation is smaller, but there was a significant increase between day 
1 and day 4. In terms of BNP, there is now evidence to suggest that repeating the 
measurement weeks to months after the ACS could enhance risk stratification beyond the 
information provided by the baseline BNP.170, 171 When adjusting for CRP it could be argued 
that using values obtained at 3 months after the event would have been better, as there are 
data suggesting that CRP levels in the acute phase after an MI are not predictive of mortality, 
while chronic levels are.116 The most likely explanation would be that the acute-phase 
response to myocardial necrosis masks the baseline CRP level which better corresponds to 
risk.  
It may be argued that the cycles of thawing and refreezing could have affected the levels of 
what was being analyzed; OPG, CgA, CXCL16, CRP and BNP. One study of OPG found 
significant differences between morning and early afternoon and after five freeze-and-thaw 
cycles compared with before.172 It seems that the available commercial ELISAs for OPG have 
marked variations in calculated serum concentrations.173 CgA is stable in vitro at room 
temperature. Plasma levels are not affected by repeated thawing-refreezing cycles but are 
elevated in liver and renal failure as well as in several neuroendocrine tumors.174 In Paper II, 
the stability of CXCL16 in serum and the small variation observed in relation to food intake 
and time of day would make CXCL16 easy to use clinically if other studies were to confirm 
our results relating to its association with prognosis.  
In Paper III, we made adjustments for the risk factors that make up the GRACE score instead 
of staying with the conventional risk factors that we used in Papers I, II and IV. Since we 
actually corrected for more variables than the GRACE score, it would seem that we 
attenuated the relationships more in Papers I, II and IV than in paper III. Since the GRACE 
score is used around the world and is well documented,175 we felt this made our findings 
easier to judge from a contemporary clinical perspective.  
The way we have defined new HF is not the same in all four papers. In Papers I, II and IV, 
HF was defined as rehospitalization with a primary ICD-9 code 428 or ICD-10 code I50, but, 
in Paper III, we also included patients who developed HF symptoms, Killip class > 1, during 
the index hospitalization.  
The definition of MI used in the four papers is the one that was in use during the inclusion 
period. The new definition of MI, where a lower cut-off for infarction markers has been 
established, has naturally increased the number of people receiving a diagnosis of MI each 
year, while also reducing the diagnosis-related mortality. For our studies, this means that 
some patients who were diagnosed with UAP in relation to inclusion and data collection in 
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the study would today receive a diagnosis of NSTEMI instead and some patients who did not 
fulfil the inclusion criteria for UAP would do so now, with the more sensitive troponin assays. 
This has to be borne in mind when relating the data to contemporary data and patients. Also, 
treatment has changed in patients with MI, with more patients receiving revascularization 
today which explains part of the decrease in mortality since the inclusion period of 
PRACIS.176 With the continuing improvement of treatment, we will (thankfully) never be 
able to base our risk estimates for the patient having an ACS today, on patients treated exactly 
them. 
Over time, the “golden standard” of statistical measures used in articles on prognostic markers 
has changed. From mere demonstrations of a difference in circulating concentration between 
those suffering a certain event and those who do not (using all study subjects or only case 
control), to a comparison of how much a marker contributes, in addition to clinical variables 
in C-statistics with complicated goodness of fit testing for the model, as is possible today. It 
would naturally be interesting to be able to analyze our data further.  
 
Findings 
Prediction of HF 
 
In Paper I, OPG was related to HF rehospitalizations, even after adjustment for conventional 
risk factors, LVEF, TnI, CRP and BNP. This suggests that its association with HF goes 
beyond only predisposing factors such as hypertension and diabetes, a large MI with 
corresponding high maximum levels of markers of myocyte necrosis and pre-existing or 
developing myocardial dysfunction (as assessed by LVEF and BNP). OPG has been shown to 
reflect the activity of the OPG/RANK/RANKL axis, which is involved in matrix degradation 
and remodelling.177, 178 Serum levels of OPG are increased in patients with LV pressure 
overload due to aortic stenosis and decreased after valve replacement.134 Both serum levels 
and myocardial expression are increased in HF.179 In Paper II, CXCL16 was associated with 
HF rehospitalizations after adjustment for conventional risk factors. We found an association 
between CXCL16 and disease severity evaluated by ECG abnormalities (ST elevation and Q-
wave on admission), maximum levels of markers of myocardial injury (TnT and CK-MB) and 
indices of systolic dysfunction (LVEF and proBNP). Like OPG, it is expressed in the 
myocardium of HF patients151 and levels are increased in HF patients where they correspond 
to disease severity. CXCL16 is implied in matrix degradation as it increases MMP 
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expression.150 Not surprisingly, given the results in Papers I and II, the combination of 
CXCL16 and OPG predicted HF both during the index hospitalization and during long-term 
follow-up, also after adjustment for the GRACE score. It has been suggested that OPG and 
CXCL could be mediators, and not just markers, in the development of HF. Our data lend 
further support to these hypotheses. In paper IV, CgA also predicted HF rehospitalizations. 
Like OPG and CXCL16, CgA is produced in the myocardium of HF patients who also have 
higher circulating levels than controls.162 For CgA, part of the explanation of the relationship 
could be the increase in sympathetic tone seen after MI.180 
 
Prediction of recurrent MI 
 
Generally, MI appears to be more difficult to predict than HF, perhaps since the development 
of HF is usually a slower and steadier process than the plaque rupture that is so often the 
pivotal point in the transition from stable atherosclerosis to an acute event. Of the biochemical 
markers studied in this thesis, only CXCL16 predicted recurrent MI after adjustment for 
clinical risk factors. OPG and CgA were associated with the recurrence of MI in univariate 
analysis but not after adjustment. There was no relationship with a history of MI for OPG or 
CXCL16, while there was for CgA. Both the OPG/RANK/RANKL axis as represented by 
OPG, and CXCL16 play possible roles in the transition from a stable to a vulnerable plaque, 
through their matrix-degrading effects as well as via pro-inflammatory effects.150, 179 There 
may also be an effect by the RANK/RANKL/OPG axis in plaque calcification126, 181, 182 and 
CXCL16 is involved in SMC migration and lipid metabolism.146, 183 
 
Prediction of mortality 
 
OPG, CXCL16 and CgA levels all predicted mortality in univariate analysis and, as shown by 
multiple regression analyses, they added independent prognostic information to clinical risk 
factors and, in the case of an OPG/CXCL16 combination, to the GRACE score. In our 
patients, CV mortality was, as expected, the leading cause of death. The association with HF 
development and the subsequent risk of malignant arrhythmia, and the risk of sudden death 
due to ischemia, perhaps following plaque rupture, help explain those deaths. For the non-CV 
mortality, several associations of these biomarkers with diseases associated with a shortened 
life expectancy have been observed. Higher levels of CgA have been demonstrated in several 
conditions with higher mortality, such as breast, prostate,184 lung, uterus, pancreas, GI and 
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head and neck cancers, hematological malignancies, neuroendocrine tumors, renal failure174 
and liver cirrhosis,174 as well as Parkinson´s disease and rheumatoid arthritis. OPG can inhibit 
the apoptosis-inducing activity of TRAIL and thereby possibly aid the survival of cancer cells 
expressing OPG. Elevated OPG levels are increased, and associated with a poorer prognosis, 
in several cancer forms such as bladder carcinoma, 185 gastric carcinoma186 and prostate 
cancer.187 Serum CXCL16 levels are elevated in systemic sclerosis,188multiple sclerosis (MS) 
and systemic lupus erytematosus (SLE).189 We did not, however, investigate the specific 
cause of death in patients who died due to non-CV causes. This may be of interest for future 
research, as IL-18 was recently found to be unexpectedly associated with non-CV mortality in 
the PRACSIS study.190 
 
Eggers and coworkers demonstrated a C-statistic for the GRACE score of 0.78 for 6-year 
mortality in chest pain patients. However, to the best of our knowledge, Study III is the first 
published article to evaluate the GRACE score in a long-term population of ACS patients.  
 
The finding that OPG + CXCL16 concentrations obtained in the acute phase and 3 months 
later are similarly predictive of mortality and HF development is interesting. It indicates that 
high circulating levels, whether caused by an acute inflammatory state or chronic 
inflammation in atherosclerosis, are indicative of prognosis. 
 
Prediction of stroke 
Carotid atherosclerotic plaque as detected by ultrasound is a risk factor for ischemic stroke.191, 
192 OPG is present in,130 and predicts progression of, carotid atherosclerotic plaques193 and is 
also positively correlated with plaque echolucency,194 which is believed to mark the rupture-
prone plaque195, 196 and correlates with risk factors including inflammation and endothelial 
dysfunction.197, 198 CXCL16 expression is increased in carotid atherosclerotic plaque 
compared to normal vessel wall146, 183 and an association between CXCL16 levels and 
ischemic stroke was recently demonstrated.199 CgA is increased in hypertension, an important 
risk factor for stroke.200 However, none of the biomarkers we studied was predictive of stroke 
in our patients.  
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Concluding remarks 
Could these three markers that we studied be of value for the clinician in risk assessment of 
the patient with ACS? 
When using the three criteria postulated by Morrow and de Lemos in Circulation in 200756 to 
appraise OPG, CXCL16, a combination of the two and CgA, we can say “yes” to the first 
two.  
1. Can the clinician measure the biomarkers? Yes, as they are quantified by an ELISA using 
commercially available antibodies (OPG, CXCL16) and by a commercially available ELISA 
assay (CgA).  
2. Does the biomarker add new information? Yes, even after adjustment for conventional risk 
markers, serum levels of OPG, CXCL16 and CgA provide information on both long-term 
mortality and rehospitalizations due to HF in patients with ACS.  
3. Will the biomarker help the clinician to manage patients? More data on risk prediction in 
other ACS patient populations are needed before this question can be answered. Further 
studies should include reclassification rates and evaluation of the frequency of false-positive 
and false-negative errors  
 
Will these markers, or combinations of them, then change the way we tailor treatment for 
ACS patients? At the moment this is not likely, since there are available tools for risk 
prediction that are at least as effective that are still not being used in everyday clinical work. 
Moreover, it can be argued that the cost of providing additional risk information with markers 
for individual patients is too high and the potential benefit too small – which will naturally be 
true unless the risk model is allowed to influence treatment, which will require further studies. 
Even if new biomarkers have improved risk prediction in ACS, it is important to underscore 
that, so far, none of them has been proven to alter the outcome of interventions. In previous 
studies that have looked at adding different markers to clinical prediction models, the 
improvement of risk stratification was most obvious among the subjects initially classified as 
being at intermediate risk. Several studies evaluating multimarker strategies for risk 
prediction had been published when the Atherosclerosis Risk in Communities Study (ARIC) 
was published and intensified the discussion of the value of markers. It assessed 19 novel risk 
markers, including CRP, in addition to conventional risk factors, in the prediction of HD201. 
CRP did not add significantly to the C-statistic and neither did most of the other markers that 
were evaluated. It may be argued that there is no need for more laboratory markers for risk 
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stratification since INTERHEART showed that more than nine in every ten MIs were 
associated with nine easily measurable clinical risk factors. 
Perhaps, in order for patients to receive the additional benefits of more individualized 
treatment that improved risk stratification could make possible, we need a simpler schedule 
for the clinician to use. This is where I believe there is a place for a multimarker strategy, 
containing both clinical data and a proven set of valuable biomarkers. In prognostication, as in 
life, it is probably best to rely on more than just one source of information.   
Anna M Jansson 
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Conclusions 
 
• OPG, CXCL16 and CgA independently predict mortality in ACS patients. 
• OPG, CXCL16 and CgA independently predict rehospitalizations due to HF, but not 
due to stroke. All three predict hospitalizations due to MI in univariate analysis, but 
only CXCL16 does so after adjustment for clinical risk factors.  
• Baseline values of CXCL16 and OPG, as obtained in a stable phase 3 months after the 
acute event, are equally predictive of mortality and morbidity as levels obtained in 
direct relationship to an ACS. 
• Levels of OPG and CXCL16 are increased in relation to an ACS. While CXCL16 
levels increased between day 1 and day 4, there was a concurrent non-significant 
decrease in OPG. 
• CXCL16 is a stable marker, only slightly affected by circadian and postprandial 
variation, as well as by the freezing and thawing of serum. 
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